Magellan Stem Cells Chief Operations Officer Nick Bleisner has addressed the 11th Immunotherapy, Gene Therapy and Cell Therapy Convention in Beijing, China, as a special guest speaker.
Nick’s subject matter is one of the most critical parts of advanced cell therapy development, the scale-up and stability challenges involved in supplying a large-scale Phase III stem cell trial.
Nick told the conference that as cell therapies move from early promise to late-stage clinical development, the conversation has to go beyond innovation alone.
“Reliable supply, process consistency, product stability, logistics, quality systems and manufacturing readiness all become mission-critical if we want to deliver therapies to patients at scale,” he told hundreds of conference delegates.
Nick shared lessons from the cell-manufacturing front line and contributed to the broader discussion on what it really takes to successfully manage cell therapies through the development phase and on to robust clinical execution.
The conference’s focus was on technological breakthroughs, clinical translation, CMC challenges and commercialisation in the CGT field. It also aimed to connect representatives of government, industry, academia, research institutions, hospitals and capital with advances in the field.
The 11th Immunotherapy, Gene Therapy and Cell Therapy Convention was held in Beijing on 16 and 17 April.